One of the largest med-tech deals of 2023 was wiped off the charts when Medtronic plc terminated a $738 million agreement to acquire South Korean wearable insulin patch maker Eoflow Co. Ltd., citing “multiple breaches” under its agreements, on Dec. 6.

Artificial Intelligence (AI) driven tools have the ability to design new drugs, with a bit of help from humans, said Anders Hogner, from Astrazeneca plc’s R&D department at the Bio-IT World Conference & Expo Europe in London. “We don’t have anything out there yet,” he added, but the company appears to be working on it.

Researchers have developed a new approach for the development of improved CAR T cells with bifunctional degraders, which linked ubiquitin to an endogenous target protein. The key to the design was the use of multispecific protein degraders and E3 ligases, which increased the proliferation of CAR T cells and their antitumor potency. This combination can be adapted to different uses of cell therapies.

Artificial Intelligence (AI) driven tools have the ability to design new drugs, with a bit of help from humans, said Anders Hogner, from Astrazeneca plc’s R&D department at the Bio-IT World Conference & Expo Europe in London. “We don’t have anything out there yet,” he added, but the company appears to be working on it.

Prism Biolab Co. Ltd. has entered into a drug discovery, license and collaboration agreement with Eli Lilly & Co.

Wubin Bai, assistant professor of applied physical sciences, and members of his lab at UNC-Chapel Hill have developed a wearable, wireless sensing patch for deep tissue monitoring of multiple biometric indicators, including tissue oximetry, pulse oximetry, photoplethysmography, heart pulsation, and respiration.

Researchers from New York University College of Dentistry’s Pain Research Center in collaboration with the University of Pittsburgh found a candidate for chronic pain treatment among a library of 27 million compounds.

Novel approaches are needed to improve anti-inflammatory drug delivery to the brain, particularly to glial cells, in order to reduce neuroinflammation.

Burnet Institute has entered into a research license and option agreement with Argenx SE for Burnet’s Stellabody technology.

Postera Inc. has announced a multitarget collaboration with Amgen Inc. that seeks to leverage Postera’s artificial intelligence (AI) platform, Proton, an innovation in generative chemistry and synthesis-aware design, and Amgen’s drug discovery expertise, to advance up to five small-molecule programs.